(VIANEWS) – Vaalco Energy (EGY), Neurocrine Biosciences (NBIX), Axcelis Technologies (ACLS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Vaalco Energy (EGY)
47% sales growth and 11.05% return on equity
VAALCO Energy, Inc., an independent energy company, acquires, explores for, develops, and produces crude oil and natural gas. The company holds Etame production sharing contract related to the Etame Marin block located offshore in the Republic of Gabon, West Africa. It also owns interests in an undeveloped block offshore Equatorial Guinea, West Africa. VAALCO Energy, Inc. was founded in 1985 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Vaalco Energy has a trailing twelve months EPS of $0.31.
PE Ratio
Vaalco Energy has a trailing twelve months price to earnings ratio of 14.06. Meaning, the purchaser of the share is investing $14.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.05%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 48.9%, now sitting on 402.5M for the twelve trailing months.
Moving Average
Vaalco Energy’s worth is under its 50-day moving average of $4.46 and above its 200-day moving average of $4.28.
Previous days news about Vaalco Energy(EGY)
- According to Zacks on Wednesday, 24 January, "Investors might want to look at some better-ranked stocks in the energy sector, such as Vaalco Energy (EGY Quick QuoteEGY – Free Report) , Oceaneering International (OII Quick QuoteOII – Free Report) and Enbridge (ENB Quick QuoteENB – Free Report) . "
- According to Zacks on Thursday, 25 January, "Investors might want to look at some other top-ranked stocks in the energy sector, such as Vaalco Energy (EGY Quick QuoteEGY – Free Report) , Enbridge (ENB Quick QuoteENB – Free Report) and Harbour Energy (HBRIY Quick QuoteHBRIY – Free Report) . "
2. Neurocrine Biosciences (NBIX)
25.1% sales growth and 10.77% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $1.9.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 69.49. Meaning, the purchaser of the share is investing $69.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.77%.
Moving Average
Neurocrine Biosciences’s value is way above its 50-day moving average of $119.97 and way higher than its 200-day moving average of $107.17.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Neurocrine Biosciences’s EBITDA is 84.17.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 28.4% and 234.2%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.6%, now sitting on 1.78B for the twelve trailing months.
3. Axcelis Technologies (ACLS)
13% sales growth and 32.8% return on equity
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia Pacific. The company offers high energy, high current, and medium current implanters for various application requirements. It also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. It sells its equipment and services to semiconductor chip manufacturers through its direct sales force. Axcelis Technologies, Inc. was founded in 1978 and is headquartered in Beverly, Massachusetts.
Earnings Per Share
As for profitability, Axcelis Technologies has a trailing twelve months EPS of $6.99.
PE Ratio
Axcelis Technologies has a trailing twelve months price to earnings ratio of 16.61. Meaning, the purchaser of the share is investing $16.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.8%.
4. H&E Equipment Services (HEES)
9.7% sales growth and 39.47% return on equity
H&E Equipment Services, Inc. operates as an integrated equipment services company. The company operates in five segments: Equipment Rentals, Used Equipment Sales, New Equipment Sales, Parts Sales, and Repair and Maintenance Services. The Equipment Rentals segment provides construction and industrial equipment for rent on a daily, weekly, and monthly basis through a fleet of approximately 42,725 pieces of equipment. The Used Equipment Sales segment sells used equipment through retail sales force primarily from its rental fleet, as well as inventoried equipment that are acquired through trade-ins from equipment customers. The New Equipment Sales segment sells new construction equipment through a professional in-house retail sales force. The Parts Sales segment sells parts for the equipment customers, as well as offers for its rental fleet. The Repair and Maintenance Services segment serves its rental fleet and equipment owned customers, as well as offers ongoing preventative maintenance services to industrial customers. It also provides ancillary equipment support activities, including transportation, hauling, parts shipping, and loss damage waivers. The company's rental fleet consists of hi-lift or aerial work platforms, cranes, earthmoving and material handling equipment, and others. It serves industrial and commercial companies, construction contractors, manufacturers, public utilities, municipalities, maintenance contractors, and various other industrial account customers. As of December 31, 2021, the company had a network of 102 service facilities in the Pacific Northwest, West Coast, Intermountain, Southwest, Gulf Coast, Southeast, and Mid-Atlantic regions of the United States. H&E Equipment Services, Inc. was founded in 1961 and is headquartered in Baton Rouge, Louisiana.
Earnings Per Share
As for profitability, H&E Equipment Services has a trailing twelve months EPS of $4.63.
PE Ratio
H&E Equipment Services has a trailing twelve months price to earnings ratio of 10.49. Meaning, the purchaser of the share is investing $10.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 39.47%.
Moving Average
H&E Equipment Services’s worth is higher than its 50-day moving average of $47.44 and way higher than its 200-day moving average of $43.84.
5. ICON plc (ICLR)
6.5% sales growth and 5.97% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $6.22.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 41. Meaning, the purchaser of the share is investing $41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.97%.
Moving Average
ICON plc’s worth is below its 50-day moving average of $269.48 and higher than its 200-day moving average of $241.90.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.8%, now sitting on 8.02B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 9.9% and 20%, respectively.
Yearly Top and Bottom Value
ICON plc’s stock is valued at $255.00 at 05:22 EST, way below its 52-week high of $288.50 and way above its 52-week low of $181.92.
